+1-888-308-5802     
News Contact Us

Cipla agrees to buy U.S.-based Avenue Therapeutics in a $215m deal

Author : Pankaj Singh | Published Date : 2018-11-14 

Pharmaceutical drug giant Cipla recently confirmed that its U.S.-based subsidiary, InvaGen Pharmaceuticals, Inc. has signed definitive agreements for acquiring specialty pharmaceutical company Avenue Therapeutics, also from the U.S. The deal is reported to be valued at US$ 215 million (approx. Rs 1,560 crore).

A Fortress Biotech company, Avenue Therapeutics, Inc. is focused on developing and commercializing the painkiller intravenous (IV) Tramadol. Cipla informed in its statement that the company aims to acquire Avenue Therapeutics in two stages.

According to the company, InvaGen or its affiliates would acquire shares amounting to a 33.3 percent stake in Avenue’s capital stock for US$35 million on a fully diluted basis. This will be achieved by the issuance of new shares by Avenue, the company mentioned. At the same time, with the stock issuance closing, three members will be appointed by InvaGen or affiliates, including one independent member, on the seven-member board of directors of Avenue.

The second stage would involve InvaGen or its affiliates acquiring the remaining common stock shares of Avenue for up to US$180 million in the aggregate. The closing of the second stage is subject to certain conditions, such as those associated with USFDA approval and the absence of restrictions pertaining to IV Tramadol, including Risk Evaluation and Mitigation Strategy (REMS), Cipla mentioned.

Umang Vohra, Managing Director & Global Chief Executive Officer of Cipla, said that the company’s investment in the proposed purchase of Avenue would help establish its presence in the US specialty business market. It aligns with Cipla’s intention to develop a specialty drug pipeline in the country, he added.

The company said this transaction would be subject to the approval from stockholders of Avenue Therapeutics and regulatory approvals, besides other closing conditions. Market reports show that Cipla shares were trading at Rs 528.25 per share on BSE at the time, down by 0.69 percent.

About Author

Pankaj Singh

Pankaj Singh

Endowed with a post graduate degree in management and finance, Pankaj Singh has been a part of the online content domain for quite a while. Having worked previously as a U.K. insurance underwriter for two years, he now writes articles for fractovia.org and other online portals. He can be contacted at- [email protected] | https://twitter.com/PankajSingh2605

Related News

Chipmaker TSMC mulls over Germany for first Europe chip plant

Published Date: 2021-07-27         Author: Pankaj Singh

Taiwan Semiconductor Manufacturing Co Ltd (TSMC) stated that it is too early to talk about its factory expansion in Germany and that the talks are in the initial phases as the European Union seeks to reduce chip imports amid the supply shortage. The European Commission had conducted discussions w... Read More

COVID-19 cases surge in Australia, police warn of protest repeat

Published Date: 2021-07-26         Author: Pankaj Singh

Despite a weeks-long stay-at-home order, Australias most populated state reportedly recorded an increase in new COVID-19 cases, and police swore to suppress any recurrence of the raucous anti-lockdown rally over the weekend. New South Wales, which had imposed a lockdown in Sydney to curb the wide... Read More

LG commits to sustainability mission, aims to go 100% renewable by 2050

Published Date: 2021-07-23         Author: Pankaj Singh

South Korean multinational electronics firm LG Electronics Inc. recently announced its plans to transition to 100% renewable energy by 2050 as part of its sustainability strategy. For the record, the firm had earlier committed to carbon neutrality via the Zero Carbon 2030 initiative, which aims t... Read More

© 2021 Fractovia. All Rights Reserved